Trial Profile
A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Lenzilumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Proof of concept
- Acronyms ZUMA-19
- Sponsors Gilead Sciences; Kite Pharma
- 13 Dec 2022 Results (at data cutoff 9 May 2022; n=6) of phase 1 were presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 26 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 27 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2022.